anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Embodiments of the disclosed system calculate a single score (&#34;SDIS&#34;) for dietary intake over a period of time. In one embodiment, the single score is an indication of whether a subset of measurable nutrients (determined to be indicative of nutritional health) and energy consumed are within a healthy range that is specific to a user. Embodiments of the disclosed system determine whether each nutrient consumed falls within a healthy range. This range may be calculated by, for example, using a plurality of possible minimum intake values and an upper limit (if one exists) for each nutrient. Similarly, the system determines whether the energy consumed falls within a healthy range. The averaged nutrient score is then multiplied by an energy score to arrive at the final score. In an embodiment, the system particularly emphasizes the impact of the energy score treated as a multiplier rather than as a nutrient.
PROBLEM TO BE SOLVED: To provide a perfume pack aiming convenience and multiple uses as a measure for promoting the economical effect and consumption of the perfume. SOLUTION: A superposed article as a packing material 1 has ventilation holes 1a on one side at an equal distance and a wholly adhesive surface on the other side. A mat 2 impregnated with a perfume is placed at a place corresponding to the ventilation holes 1a in the superposed article. Both the surfaces of the superposed article are sealed with seals 3, 4, followed by half or wholly cutting the boundary portions of the packs. One pack is a standard dosage. When the seals 3, 4 are peeled, the diffusion of the perfume is started from one side, and the adhesive surface 1b appears on the other side. Namely, the perfume pack is &#39;a sticker perfume&#39;, and is used on the back collar side of a garment, the back surface of a name plate, a cap or the like.
Stable solutions of polythionic acid or polythionates substantially free from elementary sulphur are obtained by adding to the solutions organic compounds containing at least one nitrogen atom in the molecule and belonging to one or more of the following types of compounds: amino acids, condensation products of amines and aldehydes, hydrazine, hydrazine compounds and compounds of the following molecular configuration: &lt;FORM:0632929/III/1&gt; p  , R1CONHR2 and R.SO2NH2, where R, R1 and R2 are hydrogen, aliphatic or aromatic radicals.  The wetting agents of Specification 632,928 and/or the substances of Specification 632,927 which are capable of forming in the solution compounds of metals in the oxidized and reduced states, may also be present.  The examples relate to the stabilization of solutions of pentathionic acid, sodium pentathionate, potassium pentathionate, potassium hexathionate, potassium tetrathionate and alkali metal tetrathionates in general.ALSO:Cosmetics and external medicines comprise solutions of polythionic acid or polythionates substantially free from elementary sulphur, said solutions being stabilized by the addition thereto of organic compounds containing at least one nitrogen atom in the molecule and belonging to one or more of the following types of compounds: amino acids, condensation products of amines and aldehydes, hydrazine, hydrazine compounds and compounds of the following molecular configuration &lt;FORM:0632929/VI/1&gt; &lt;FORM:0632929/VI/2&gt; R1CONHR2 and R.SO2NH2 in which R. R1 and R2 designate hydrogen or an aromatic or aliphatic radical.  The wetting agents of Specification 632,928 and/or the substances of Specification 632,927, which are capable of forming in the solution compounds of metals in the oxidized and reduced states may also be present.  The examples relate to the stabilization of solutions of pentathionic acid, sodium pentathionate, potassium pentathionate, potassium hexathionate, potassium tetrathionate and alkali metal tetrathionates in general. p
The invention provides a method for treating a patient in need of  ex vivo  perfusion of his/her blood through a pig organ comprising first passing plasma from the patient over a column coupled to anti-human immunoglobulin antibodies, thereby removing a significant portion of the immunoglobulin from the patient&#39;s plasma, recombining the patient&#39;s immunoglobulin-depleted plasma with the patient&#39;s red blood cells, perfusing the patient&#39;s immunoglobulin-depleted blood through the pig organ, and then reinfusing the blood to the patient. Depletion of immunoglobulin removes anti-pig natural antibodies which would otherwise cause a hyperacute rejection reaction in the pig organ, thus quickly destroying the organ within 2-6 hours. The invention allows a single pig organ to function well in  ex vivo  perfusion for a much longer time, without signs of hyperacute rejection in the organ. The invention is especially useful in cases of acute liver failure where  ex vivo  perfusion of the patient&#39;s blood through a pig liver can bring the patient out of hepatic coma and bridge the patient to liver transplant. In some cases, the patient&#39;s liver may begin functioning on its own again after the treatment, thus altogether abrogating the need for liver transplant. The invention is also directed to the use of anti-human immunoglobulin antibodies in the manufacture of a column coupled to said antibodies for the pre-treatment of the plasma of a patient prior to  ex vivo  perfusion of the patient&#39;s blood through a pig organ.
PURPOSE:To obtain a new compound, having strong inhibiting action on proliferation of a cancerous cell and useful as a carcinostatic agent. CONSTITUTION:This compound of formula I (R1 and R2 are H or OH-protecting group), e.g. N&#39;-(O,O-isopropylidene)glyceryl-N-methyldeacetylcolchiceinamide. The compound of formula I is obtained by reacting N- methyldeacetylcolchiceinamide of formula II with glyceraldehyde of formula III in the presence of preferably a dehydrating agent (e.g. molecular sieves) in a solvent such as benzene to provide a Schiff base of formula IV, which is then reduced with a reducing agent (e.g. sodium cyanoborohydride) at -5 to +20 deg.C to afford the compound of formula I. The reaction is carried out by using 0.8-2.5mol compound of formula III and 0.8-1.2mol reducing agent based on 1mol compound of formula II.
PURPOSE:To obtain the titled pharmaceutical composition stable to heat and suitable for the preparation of powder, fine granules, granules, tablets, capsules, etc., by mixing ubidecarenone known as a cardiovascular agent, with isopropyl alcohol as a solvent and precipitated silicic anhydride as an adsorbent. CONSTITUTION:1pt.wt. of ubidecarenone is dissolved in &gt;=3pts.wt., preferably &gt;=7.5pts.wt. of isopropyl alcohol, and the ubidecarenone is adsorbed by adding &gt;=0.5pt.wt., preferably &gt;=2pts.wt. of precipitated silicic anhydride to the solution to obtain the objective stable pharmaceutical composition of ubidecarenone. The migration of ubidecarenone with solvent during the drying stage can be prevented and an uniformly adsorbed stable product can be obtained. It can be heated at &gt;=48 deg.C without causing the formation of spots nor lowering of the titer.
NEW MATERIAL:A compound expressed by formula I (R&lt;1&gt; to R&lt;3&gt; are H or OH, except that both are simultaneously H; R&lt;4&gt; is H or lower alkyl) and salts thereof. EXAMPLE:Methyl 4-{2-[4-(2-hydroxy-1-methylethyl)benzamido]ethoxy}benzoate. USE:A biosynthesis inhibitor for fatty acids and medicine having expected effects on suppression of obesity and prevention and treatment of fatty liver. PREPARATION:A compound expressed by formula II is reacted with a compound expressed by formula III according to the reaction formula to afford the compound expressed by formula I. The reaction is carried out at -10 deg.C to ambient temperature by using a condensing agent, such as N,N&#39;-dicyclohexylcarbodiimide, in a suitable solvent, e.g. methylene chloride or THF.
Methods and compositions for modulating aging genes or their targets for the treatment or prevention of senescence or symptoms thereof have been developed based on the discovery of naturally occurring inhibitory nucleic acids, in particular lin-4 miRNA, that downregulate genes involved in senescence, lifespan, or age-related disorders. Representative aging genes include, but are not limited to lin-4, lin-14, let-7, lin-28, egl-35 and lin-42. Methods for identifying modulators of aging genes and targets of aging genes are also provided. The disclosed compositions are useful as diagnostics. These can be used in assays to compare genes in normal individuals, with those who are aging well or who demonstrate early senescence, and with those who have age-related disorders such as Parkinson&#39;s and Alzheimer&#39;s. The genes can be used to study the pathways and mechanisms involved in aging and age-related disorders. These genes can be used as drug targets, or in drug design, to develop drugs that can inhibit one or more characteristics of senescence or age-related disorders. These compositions should be effective therapies for treating or slowing the effects of one or more symptoms or characteristics of age-related disorders resulting from activation or over-expression of aging genes. Compositions that alter the expression of particular aging genes affecting the insulin-like signal pathway are described. Suitable compositions described herein include, inhibitory nucleic acids and small molecules, in particular miRNA.
1318560 Mite antigen MUNDIPHARMA AG 7 Sept 1970 [13 Oct 1969] 42792/70 Heading A5B [Also in Division B1] An antigen obtained from mites is characterized by the following properties: (a) white to cream colour, (b) a positive reaction to the Biuret test, xanthoproteic test and Millon&#39;s test, (c) solubility in water, glycerol, and propylene glycol and insolubility in benzene, petroleum, diethyl ether and halogenated hydrocarbon solvents, (d) precipitation from aqueous solution by AlCl 3 , ZnCl 2 , AgNO 3 , tannic acid phosphotungstic acid and trichloroacetic acid, (e) an elemental composition of C:45-55%, H:6-8%, N:14-20%, O: 19-25% and S.6-1.8%, (f) an isoelectric point between pH4 and pH5, (g) a thin layer chromatograph, using butanol-water-acetic acid in ratio of 5:4:1 as eluent and ninhydrin as developer, comprising at least one of the following bands (i) an orange pinkish tinged band of Rf 0.16, (ii) a pink band at Rf 0.28 and (iii) an orange-pinkish band at Rf 0.4, the relative intensities of the bands, where more than one are present being (i) is more intense than (iii) which is more intense than (ii), (h) an allergenic tissue reaction when administered intercutaneously to a mammal which is allergic to mites and (i) stimulation of mite antigen antibody formation when administered systemically to a mamal. The mites may be of species Dermatophagoides Pteronyssinus, D. Culinae, D. Farinae, Acarus Siro, Glycophague Domesticus, E. Mayrei or I. Putrescenticie. The antigen may be extracted with an aqueous solvent purified, e.g. by precipitation and resolution, by dialysis and/or by absorption and elution, and isolated by evaporating the solvent. The antigen may be compounded with a solid carrier in powders, granules or tables or with a liquid carrier as an injectable solution. This liquid may be used to test for an allergic response to mites, e.g. in treatment of asthma, for desensitization of allergic patients. A diagnostic device comprises a microbore capillary tube containing the liquid sealed at both ends with wax, clay, rubber or plastics material. In use, this is broken and the liquid allowed to flow on to the skin whilst the broken tube is used to scratch it. The liquid composition may also be injected into animals to produce an antiserum.
NEW MATERIAL:A compound shown by formula I (R&lt;1&gt; is H, 2-6C alkyl or 2-6C acyl; R&lt;2&gt; is H or 1-3C alkyl; compound wherein both R&lt;1&gt; and R&lt;2&gt; are H is omitted). EXAMPLE:5-Ethyl-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indole. USE:Having diuretic action, heart suppressing action, relaxing action on smooth muscle and sleep prolonging action, useful as a remedy for circulatory diseases, remedy for alimentary diseases and psychotropic agent. PREPARATION:A 4-cyanoindole derivative shown by formula II is hydrolyzed with a base such as triton B and subjected to ring closure to produce a compound shown by formula III. Then this compound is reduced with a reducing agent such as lithium aluminum hydride. The starting raw material shown by formula II is produced by reacting a compound shown by formula IV with a nitroalkane, hydrogenating and reducing the reaction product.
Uterine cervical cancer Computer-Aided-Diagnosis (CAD) according to this invention consists of a core processing system that automatically analyses data acquired from the uterine cervix and provides tissue and patient diagnosis, as well as adequacy of the examination. The data can include, but is not limited to, color still images or video, reflectance and fluorescence multi-spectral or hyper-spectral imagery, coherent optical tomography imagery, and impedance measurements, taken with and without the use of contrast agents like 3-5% acetic acid, Lugol&#39;s iodine, or 5-aminolevulinic acid. The core processing system is based on an open, modular, and feature-based architecture, designed for multi-data, multi-sensor, and multi-feature fusion. The core processing system can be embedded in different CAD system realizations. For example: A CAD system for cervical cancer screening could in a very simple version consist of a hand-held device that only acquires one digital RGB image of the uterine cervix after application of 3-5% acetic acid and provides automatically a patient diagnosis. A CAD system used as a colposcopy adjunct could provide all functions that are related to colposcopy and that can be provided by a computer, from automation of the clinical workflow to automated patient diagnosis and treatment recommendation.
PROBLEM TO BE SOLVED: To obtain a treatment agent comprising an existing treatment agent, a tourmaline jelly originated from tourmaline ore and a permanent wave liquid, excellent in luster, tension, touch, etc., and having an excellent hair-keeping power. SOLUTION: This treatment agent contains 50% of an existing treatment agent, 25% of tourmaline jelly containing tourmaline ore as a main component, and 25% of a two pack type permanent wave liquid. The powder of the tourmaline ore in an amount of 5% is especially preferably added to 25% of the tourmaline jelly in the composition. Hair is preferably coated with the treatment agent and subsequently successively subjected to a padding treatment, a combing- through treatment, a steaming treatment and a plain rinsing treatment. The existing treatment agent in the treatment agent is impregnated into hair to beautify the hair, and the OH&lt;-&gt; ions of the tourmaline jelly and the cuticles of the hair neatly collect the beautiful hair. Further, the two pack type permanent wave liquid oxidizes and fix the hair to give the hair excellent in the keeping force.
The present invention relates to positioning a patient&#39;s body part including a target relative to an imaging device that generates a radiation beam directed towards the target. Geometry data is received that describes the geometry of at least one structure located in the field of view of the imaging device. Tracking date is received that describes the spatial location and/or orientation of the at least one structure within the field of view of the imaging device. Position data is determined that incorporates the geometry date and the tracking data. The position data describes whether the location and/or orientation of the at least one structure with respect to an image trajectory is desirable. Repositioning data is determined that describes a desired location and/or orientation of the at least one structure with respect to the image trajectory. The repositioning data is output to allow repositioning of the at least one structure.
The present invention is directed to a system, method and/or computer readable medium for facilitating a new medical image interpretation workflow. There is generally provided elements or the entirety of a traditional radiology workflow environment, additional peripherals in a user&#39;s workspace, one or more CAD systems, and the methods and processes to orchestrate and the transfer of information between the user and the radiology workflow to optimize the speed, efficacy and accuracy of the image interpretation task. User actions can be monitored using peripheral devices such as eye-trackers and infer information gleaned from the user (e.g., predicting user actions based on a pattern or detecting a visual search pattern which is inadequate). Furthermore, orchestration of this information in tandem with the CAD system offers an opportunity to reduce the volume of interaction required of the user to complete the image interpretation task and/or reduce the incidence of errors during the image interpretation task. Some or all of the features disclosed in the present invention can be installed at an existing radiology workflow environment without explicit integration with the existing hardware and software. Accordingly, the present invention may be a stand-alone installation or an overlay and provides the features disclosed without the traditional elements of the radiology workflow environment having been expressly adapted to accommodate the present invention.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an image display method and device and a medical image display program which can smoothly read images when the medical images are arranged and displayed.  &lt;P&gt;SOLUTION: A discriminating part 44 mutually compares the contents of the attendant information of the four medical images 17 displayed on an image display screen 46 respectively for items and discriminates the attendant information common to all the medical images 17 as common information 53. Other attendant information than the common information 53 is specific information 54. When taking an area for displaying the attendant information as the common information 53 to be located in the side of each of non-imaging areas 52 of the four medical images 17 where other medical image 17 is not adjacently displayed and the four medical images 17 as one medical image 17, the area setting part 45 allocates the area to an area corresponding to a prescribed area when the one medical image 17 is displayed on the image setting screen 46. The area setting part 45 allocates an area for displaying the attendant information as the specific information 54 to an area located in the side of each of the non-imaging areas 52 of the four medical images 17 where other medical images 17 is adjacently displayed and symmetrical with respect to boundary lines 55 to 58 of the adjacent medical images 17.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
Iodinated pyridone derivatives of carboxylic acids of the general formula &lt;FORM:0653365/IV (b)/1&gt; wherein Y is a divalent aliphatic hydrocarbon radical containing from 5 to 9 carbon atoms, are prepared by heating 3,5-diiodo-4-pyridone with a halocarboxylic acid of the formula X-Y-COOH, wherein X is halogen and Y has the above significance, in the presence of an alkali metal hydroxide and then acidifying the reaction product.  The desired iodinated pyridone derivatives may be of the formula &lt;FORM:0653365/IV (b)/2&gt; wherein R is an alkyl group containing from 4 to 8 carbon atoms. Salts of the iodinated pyridone derivatives may be formed with inorganic or organic bases, e.g. sodium hydroxide, diethanolamine or diethylamine. In the examples the following compounds are prepared: alpha - n - butyl-, alpha - n - amyl-, alpha-n-hexyl-, alpha-isoamyl-, alpha-n-heptyl-, alpha-n-octyl- and alpha-isobutyl-3,5-diiodo-4-oxo - 1 - pyridineacetic acids. Specifications 385,214 and 396,414 are referred to.  The Specification as open to inspection under Sect. 91 refers to the preparation of compounds of the above general formula wherein Y represents any divalent hydrocarbon radical.  This subject-matter does not appear in the Specification as accepted.ALSO:An internal radiopaque is obtained by dissolving an iodinated pyridone derivative of the general formula &lt;FORM:0653365/VI/1&gt; wherein Y is a divalent aliphatic hydrocarbon radical containing from 5 to 9 carbon atoms, in an aqueous solution of an equivalent amount of sodium hydroxide, diethylamine or diethanolamine.  The Specification as open to inspection under Sect. 91, refers to internal radiopaque obtained as above but where Y represents any divalent hydrocarbon radical.  This subject-matter does not appear in the Specification as accepted.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method of grafting galactomannan-type polysaccharide polymers, preferably guar, to a functional group by irradiation with high energy electron beams in the presence of an unsaturated monomer-compressing the described functional group.  &lt;P&gt;SOLUTION: The method includes depolymerization of a grafted polymer to a pre-selected low molecular weight. The preferred galactomannan for treatment according to the method is guar gum, guar splits and hydroxypropyl guar. In a preferred embodiment the guar gum is depolymerized, preferably to a molecular weight of below about 700,000 Dalton, and most preferably to a molecular weight of between about 100,000 Dalton and about 250,000 Dalton. The depolymerized guar most preferably has a polydispersity of less than about 3.0 and is useful in oil well fracturing (hydraulic fracturing) to enhance oil production.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
The invention discloses a system and a method for packaging and distributing game chemical medicines. The innovative playable smart packaging system and method provides a variety of incentives for patients and related teams to take medications on time and in the correct dosage. The system includes a monitored drug dispensing device in communication with a plurality of computing devices or smart phones. A signal is transmitted to the computing device each time a patient dispenses a medication from the dispensing device. Upon receiving the signal, the computing device records a dispensing event, calculates a specific &#34;score&#34; for the event, and reports a cumulative &#34;score&#34; for successful dispensing of the medication for the patient. If the dispensing event signal is not received on time, the system sends a medication intake reminder to the patient. Accumulating points by correctly taking prescribed medications allows the patient and/or team to be eligible for various benefits.
&lt;P&gt;PROBLEM TO BE SOLVED: To promote absorption of magnesium, zinc and copper in the body during a meal.  &lt;P&gt;SOLUTION: The subject composition promoting the absorption of magnesium, zinc or copper comprises a difructose anhydride (DFA) as an active ingredient. The DFA is preferably DFAIII or DFAIV. The DFAIII is disaccharides in which two molecules of fructose are bound at the 1,2&#39; and the 2,3&#39;-positions. The composition can be utilized even as a medicine or a food and drink product. Excellent absorption promoting effects on Mg, Zn or Cu are produced by ingesting the DFA. Thereby, absorption of these minerals in the body can safely and remarkably be promoted.  &lt;P&gt;COPYRIGHT: (C)2004,JPO